All In Biotech

Drug Trial Radar · NCT06969430

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

A Phase 1/2, First-in-human, Multicenter, Open-label Trial Evaluating the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 154 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

154

Planned (sponsor's estimate)

Start

May 30, 2025

Primary completion

Nov 2031

Study completion Nov 2031

Sponsor

Lead sponsor
Debiopharm International SAIndustry
Sponsor type
Industry
First posted
May 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of Phase 1 is to characterize the safety and tolerability to identify the recommended dose (RD) of Debio 1562M for further development. The primary objective of Phase 2 is to evaluate the antileukemic activity of Debio 1562M.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • Debio 1562MDrug

    Administered as intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 (Dose Escalation): Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)Time frame: Up to Day 28
  2. Phase 1: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)Time frame: Up to Day 219
  3. Phase 1 (Dose Optimization): Recommended Dose (RD) of Debio 1562MTime frame: Up to Day 198
  4. Phase 2: Percentage of Participants With Complete Remission (CR) + CR with partial hematological recovery (CRh)Time frame: Up to Day 198

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Recruiting

  • Moffitt Cancer Center and Research Institute Hospital

    Tampa, Florida · Recruiting

  • University of Chicago

    Chicago, Illinois · Recruiting

  • START Midwest

    Grand Rapids, Michigan · Recruiting

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York · Recruiting

  • The Ohio Sate University

    Columbus, Ohio · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.